IV. IMMUNE RESPONSE PARAMETERS 
FREQUENCY OF EVALUATION 
PRE-TREATMENT 
HLA typing F 
Anti-CD3 reactivity L 
Response panel of allogeneic stimulator cells L 
Peripheral Blood CTL to autologous tumor target N 
POST-TREATMENT 
Injection site 
Punch biopsy/ his topat ho logy H 
Immunohistochemistry for effector cells H 
Draining lymph node biopsy 
a) T-cell proliferation assay I 
b) CTL generation versus autologous 
tumor targets I 
c) Cell Surface Markers 
Flow Cytometry: IL-2 receptor, B-7 I 
d) Histopathology I 
Delayed Type Hypersensitivity Reaction 
a) Recall antigens Candida, Trichophyt in, PPD J 
b) Irradiated autologous PBL control lxlO 6 J 
c) Irradiated autologous tumor target cells J 
lxlO 6 unpassaged from nephrectomy 
d) Irradiated autologous normal renal cells J 
lxlO 6 unpassaged from nephrectomy 
V. EVALUATION OF ANTITUMOR RESPONSE/TUMOR PHENOTYPING 
a) CT scan/MRI, chest, abdomen, pelvis K 
b) Serum markers of RCC tumor burden 
Urine beta-FGF K 
Serum Parathyroid Related Protein K 
Serum Ferritin K 
Plasma OA-519 K 
Recombinant DNA Research, Volume 17 
[329] 
